Shingrix clinical trials
Shingrix is named as an intervention in 14 current clinical trials in our China, Australia, USA, South Korea, Sweden, Denmark and Brazil registers. 3 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Guangzhou Patronus Biotech Co., Ltd (2). The most-studied condition is Herpes Zoster.
How Shingrix works
All drug targets →- Envelope glycoprotein E vaccine antigen Vaccine antigenChEMBL only
- MalariaPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297975, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Shingrix
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Shingrix
14 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Shingrix
19 conditionsAll 19 conditions
| Condition (as registered) | Trials |
|---|---|
| Herpes Zoster | 6 |
| Herpes Zoster (HZ) | 3 |
| Shingles | 3 |
| Infectious Diseases | 1 |
| Varicella-zoster Virus | 1 |
| Systemic Vasculitis | 1 |
| Spondylarthropathies | 1 |
| Psoriatic Arthritis | 1 |
| Scleroderma | 1 |
| Cardiovascular Disease | 1 |
| Dementia | 1 |
| Rheumatoid Arthritis | 1 |
| Spondylitis, Ankylosing | 1 |
| Spondyloarthritis | 1 |
| Systemic Lupus Erythematosus | 1 |
| Varicella Zoster Virus Infection | 1 |
| Vaccine-Preventable Diseases | 1 |
| Immunosuppression | 1 |
| Vaccine Response Impaired | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Guangzhou Patronus Biotech Co., Ltd | 2 |
| Immorna Biotherapeutics, Inc | 1 |
| Curevo Inc | 1 |
| Shanghai Institute Of Biological Products | 1 |
| Sinocelltech Ltd | 1 |
| Suzhou Abogen Biosciences Co., Ltd | 1 |
| Region Skane | 1 |
| Tor Biering-Sørensen | 1 |
| University of Sao Paulo General Hospital | 1 |
| EuBiologics Co.,Ltd | 1 |
| Aribio Lab Co., Ltd | 1 |
| Dynavax Technologies Corporation | 1 |
| Central Adelaide Local Health Network Incorporated | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 2 |
| Clinical trials in Australia | 3 | 1 |
| Clinical trials in USA | 2 | 0 |
| Clinical trials in South Korea | 2 | 0 |
| Clinical trials in Sweden | 1 | 0 |
| Clinical trials in Denmark | 1 | 0 |
| Clinical trials in Brazil | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Shingrix trials
How many clinical trials are testing Shingrix?
14 current trials in our China, Australia, USA, South Korea, Sweden, Denmark and Brazil registers name Shingrix as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Shingrix trials recruiting patients?
Yes. 3 of the 14 trials are recruiting: 2 with sites in China and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Shingrix clinical trials?
Guangzhou Patronus Biotech Co., Ltd (2), Immorna Biotherapeutics, Inc (1), Curevo Inc (1) and Shanghai Institute Of Biological Products (1), among 13 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Shingrix works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Shingrix works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Shingrix (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.